Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 9:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 234 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Staphylococcus Aureus Clear all
Recruiting No phase listed Observational

Effectiveness of Screening and Decolonization of S. Aureus to Prevent S. Aureus Surgical Site Infections in Surgery Outpatients

NCT06378359
View directory record Official record
Conditions
Staphylococcus Aureus Colonization, Surgical Site Infections, Healthcare Associated Infections
Interventions
Screening and decolonization for SA carriers with the 3 drug bundle, No screening for SA, no screening, Nasal povidone-iodine on surgery day plus 2 CHG pre-op showers without screening., Nasal alcohol gel on surgery day plus 2 CHG pre-op showers without screening
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 5, 2026, 9:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Building an Optimal Hand Hygiene Bundle

NCT02223455
View directory record Official record
Conditions
Hand Hygiene, Health Care Associated Infection, Compliance
Interventions
Hand Hygiene Signs
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
10
States / cities
Miami, Florida • Iowa City, Iowa • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Sep 5, 2026, 9:32 AM EDT
Completed No phase listed Observational

Risk Factors for Early Infant Colonization With Methicillin-Resistant Staphylococcus Aureus

NCT01141101
View directory record Official record
Conditions
Methicillin-resistant Staphylococcus Aureus
Interventions
Not listed
Lead sponsor
Boston Medical Center
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Sep 5, 2026, 9:32 AM EDT
Completed Phase 4 Interventional

Staph Intervention for Effective Local Defense

NCT06210594
View directory record Official record
Conditions
Staphylococcus Aureus Infection
Interventions
Mupirocin + Nozin + chlorhexidine gluconate, Education + Household supplies
Combination Product · Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Whiteriver, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 5, 2026, 9:32 AM EDT
Completed Not applicable Interventional Results available

Cost-Effectiveness Study Comparing Chlorhexidine Bathing With Active Surveillance Cultures to Prevent Methicillin-resistant Staphylococcus Aureus & Other Hospital Infections

NCT00779246
View directory record Official record
Conditions
Staphylococcal Infections
Interventions
Nasal swabs for MRSA culture, Chlorhexidine gluconate, Contact isolation
Other · Drug
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
1,518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Sep 5, 2026, 9:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Cultures Before and After Decolonization in Community Dwelling Adults With Current S. Aureus Colonization

NCT04222699
View directory record Official record
Conditions
Human Microbiome
Interventions
Mupirocin calcium ointment, 2%, Topical Chlorhexidine, 4%
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Sep 5, 2026, 9:32 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Evaluation of NDV-3A Vaccine in Preventing S. Aureus Colonization

NCT03455309
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
NDV-3A, Placebo
Biological
Lead sponsor
NovaDigm Therapeutics, Inc.
Industry
Eligibility
17 Years to 35 Years · Male only
Enrollment
382 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Fort Benning, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Sep 5, 2026, 9:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Ceftaroline for Treatment of Hematogenously Acquired Staphylococcus Aureus Osteomyelitis in Children

NCT02335905
View directory record Official record
Conditions
Hematogenously Acquired Staphylococcus Aureus Osteomyelitis, Bone Infection, Osteomyelitis
Interventions
Ceftaroline Fosamil
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Year to 17 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Sep 5, 2026, 9:32 AM EDT
Completed Not applicable Interventional

Trial of MRSA Polymerase Chain Reaction for Pneumonia

NCT02660554
View directory record Official record
Conditions
Pneumonia, Methicillin-Resistant Staphylococcus Aureus
Interventions
Polymerase Chain Reaction (PCR)
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 100 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Sep 5, 2026, 9:32 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Administering NMT to Reestablish Infant Nasal Microbiome Diversity Following Intranasal Mupirocin Treatment

NCT06805994
View directory record Official record
Conditions
Staphylococcal Aureus Infection, Microbial Colonization, Pediatric Infection, S. Aureus Colonization, Microbial Transplant
Interventions
Nasal Microbiota Transplant (NMT), Placebo
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
0 Years to 60 Years
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 5, 2026, 9:32 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation

NCT02388165
View directory record Official record
Conditions
Staphylococcal Vaccine
Interventions
Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine, Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 85 Years
Enrollment
3,450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
234
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 5, 2026, 9:32 AM EDT
Active, not recruiting No phase listed Observational

Immune Resolution After Staphylococcus Aureus Bacteremia

NCT01879761
View directory record Official record
Conditions
Immune Response To Sepsis, Staphylococcus Aureus Infection
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 5, 2026, 9:32 AM EDT
Completed No phase listed Observational

An Evaluation of a Antimicrobial Stewardship Recommendation Bundle for Staphylococcus Aureus Bloodstream Infections

NCT06211829
View directory record Official record
Conditions
Bacterial Infections
Interventions
Not listed
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years to 85 Years
Enrollment
77 participants
Timeline
2022 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Sep 5, 2026, 9:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Pharmacokinetics and Efficacy of KBSA301 in Severe Pneumonia (S. Aureus)

NCT01589185
View directory record Official record
Conditions
Pneumonia Due to Staphylococcus Aureus
Interventions
KBSA301, Placebo
Drug
Lead sponsor
Aridis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Jacksonville, Florida • Oklahoma City, Oklahoma • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2020 · Synced Sep 5, 2026, 9:32 AM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 5, 2026, 9:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Comparison of Bacterial Contamination Rates Between Isolation and Non-isolation Rooms

NCT01671358
View directory record Official record
Conditions
Methicillin-Resistant Staphylococcus Aureus
Interventions
Not listed
Lead sponsor
West Virginia University
Other
Eligibility
Not listed
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Sep 5, 2026, 9:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia

NCT05184764
View directory record Official record
Conditions
Bacteremia, Staphylococcus Aureus, Staphylococcus Aureus Bacteremia, Bacteremia Staph, Bacteremia Due to Staphylococcus Aureus
Interventions
AP-SA02, Placebo
Biological · Other
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
23
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 5, 2026, 9:32 AM EDT
Completed Phase 4 Interventional

IL-10 Stratifying Tool for Towards Antibiotic Selection for MRSaB

NCT02660346
View directory record Official record
Conditions
Bacteremia
Interventions
Daptomycin, Vancomycin, Ceftaroline
Drug
Lead sponsor
Sharp HealthCare
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
La Mesa, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Sep 5, 2026, 9:32 AM EDT
Recruiting Phase 4 Interventional

Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP

NCT05094570
View directory record Official record
Conditions
Nasal Polyps, Staphylococcus Aureus
Interventions
Dupilumab Prefilled Syringe
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 31, 2025 · Synced Sep 5, 2026, 9:32 AM EDT
Completed Phase 4 Interventional Results available

Povidone-Iodine for Nasal Decolonization

NCT05529173
View directory record Official record
Conditions
Surgical Wound Infection, Preoperative Care, Methicillin-Resistant Staphylococcus Aureus
Interventions
Povidone-Iodine 10%, 0.9% NaCl Solution
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 80 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Sep 5, 2026, 9:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Immunologic Predisposition of HIV Patients to Develop Methicillin-Resistant Staphylococcus Aureus (MRSA) Colonization and Infection

NCT00859677
View directory record Official record
Conditions
HIV Infections, Staphylococcal Infections
Interventions
Not listed
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
2
States / cities
San Diego, California • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Sep 5, 2026, 9:32 AM EDT
Completed No phase listed Observational

Community-Assoc. S. Aureus Colonization and Recurrent Infection in Pts With Uncomplicated S. Aureus Skin Abscesses

NCT02690415
View directory record Official record
Conditions
MRSA
Interventions
Antibiotics Given, Antibiotics not given
Procedure
Lead sponsor
Southern Illinois University
Other
Eligibility
6 Months to 18 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Sep 5, 2026, 9:32 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Efficacy Study of Altabax to Clear Methicillin-resistant Staphylococcus Aureus (MRSA) Nasal Colonization

NCT00856089
View directory record Official record
Conditions
Methicillin-resistant Staphylococcus Aureus
Interventions
Retapamulin
Drug
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
2
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Sep 5, 2026, 9:32 AM EDT
Completed Phase 4 Interventional Results available

Skin Structure Infections With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)

NCT00087490
View directory record Official record
Conditions
Skin/Soft Tissue Infections, Methicillin Resistant Staphylococcus Aureus (MRSA)
Interventions
linezolid, vancomycin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,077 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
76
States / cities
Montgomery, Alabama • Tucson, Arizona • Los Angeles, California + 53 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Sep 5, 2026, 9:32 AM EDT